[1] ZHAO YifanZHU QingZHU YaoLU Ming,.Research on Medication Patterns of Traditional Chinese Medicine Intervention for Osteosarcoma Based on Data Mining Analysis [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2024, (02): 27-33. [doi: 10.13424/j.cnki.jsctcm.2024.02.006]
Research on Medication Patterns of Traditional Chinese Medicine Intervention for Osteosarcoma Based on Data Mining Analysis
- Article number:
- 2096-1340(2024)02-0027-07
- Keywords:
- Key words： Data mining; Traditional Chinese Medicine; Osteosarcoma; Correlation analysis; K-means clustering
- ZTFLH:
- R681
- Code:
- A
- Abstract:
- Abstract： Objective To use data mining techniques to deconstruct the prescriptions and formulas for the differentiation and treatment of osteosarcoma in traditional Chinese medicine,and then summarize the rules of medication and formulation.Methods A multi-source database data collection method was used to establish a database of osteosarcoma prescriptions and medicines.Frequency analysis,association rule analysis,and K-means clustering analysis were used for data mining.Results This study involved 45 prescriptions and 185 types of drugs,with high-frequency drugs including Astragalus membranaceus,Glycyrrhiza uralensis,Rehmannia glutinosa,Paeonia lactiflora,Poria cocos,Angelica sinensis,Atractylodes macrocephala,Chinese yam,Fructus Psoraleae,and Codonopsis pilosula;The rule results show that the main associated drugs are Astragalus membranaceus,Rehmannia glutinosa,Angelica sinensis,and Atractylodes macrocephala;Drug K-means clustering of 10 categories.Conclusion The core formula for traditional Chinese medicine treatment of osteosarcoma is Astragalus membranaceus,Rehmannia glutinosa,Angelica sinensis,and Atractylodes macrocephala.The medication pattern mainly focuses on tonifying Qi and blood,strengthening spleen and kidney,promoting Qi and blood circulation,resolving phlegm and detoxifying.The formula pattern is based on consolidating the root and clearing the source,with spleen and kidney as the main focus,and multiple methods combined for clearing the source.
References:
［1］夏祥柱,于冬冬,李鑫.中医药治疗骨肉瘤的研究进展［J］.云南中医中药杂志,2021,42(11)：83-87.
［2］黄涛.新辅助化疗治疗骨肉瘤最新进展［J］.临床军医杂志,2016,44(3)：221-223.
［3］甘林,罗群强,夏安然.骨肉瘤的保肢治疗新进展［J］.中国医药科学,2023,13(4)：43-46.
［4］迟文成,耿雪,姜家康，等.中西医结合治疗肿瘤化疗后不良反应的研究进展［J］.实用临床医药杂志,2022,26(8)：126-130，136.
［5］王雅灵,闵大六.骨肉瘤化疗耐药分子机制的相关研究进展［J］.癌症进展,2016,14(4)：311-315.
［6］赵福来,常君丽,支文兰，等.中药有效成分防治骨肉瘤转移作用与机制研究进展［J］.世界科学技术-中医药现代化,2022,24(2)：482-489.
［7］浦飞飞,陈凤霞,夏平，等.骨肉瘤化疗耐药机制及中医药逆转化疗耐药的研究进展［J］.癌症进展,2022,20(23)：2388-2391，2421.
［8］李冬云,许晶,侯丽，等.中医药抗肿瘤多药耐药领域的守正创新研究［J］.医学研究杂志,2021,50(11)：1-4，15.
［9］刘云霞,徐叶峰,李帅,等.三草愈疡汤防治骨肉瘤大剂量甲氨蝶呤化疗后口腔黏膜炎的临床研究［J］.中华中医药杂志,2019,34(10)：4942-4946.
［10］刘云霞,徐叶峰,李梦芸，等.清化复肝汤防治骨肉瘤甲氨蝶呤化疗性肝损伤的临床研究［J］.浙江中医杂志,2017,52(2)：83-84.
［11］唐德才,吴庆光.中药学［M］.3版.北京：人民卫生出版社,2017：37-376.
［12］朱垚,陆明,杨涛.中医临床医案数据挖掘研究数据规范化标准QB/GL?MCT?102-2019［S］.南京：江苏地区备案企标,2019.
［13］杨涛,陆明,朱垚.基于FP-Growth的中医药数据关联分析平台的设计和应用［J］.时珍国医国药,2016,27(12)：3050-3052.
［14］李中梓.医宗必读［M］.北京：中国中医药出版社,2018：252-259.
［15］林洪生,张英.从“扶正培本”到“固本清源”——中医药治疗肿瘤理论的传承与创新［J］.中医杂志,2016,57(4)：295-298.
［16］李鹏飞,段戡,邹旨龙.从健脾益肾法论治骨肉瘤［J］.大众科技,2018,20(11)：41-43.
［17］张介宾.景岳全书［M］.北京：中国中医药出版社,2017：512-536.
［18］李晓伟,杜明昌,曹学伟.扶正法对骨肉瘤生长转移的干预实验研究［J］.中华肿瘤防治杂志,2008,15(22)：1721-1723.
［19］吴素珍,李加林,陈水亲,等.硫酸酯化当归多糖抗肿瘤实验研究［J］.时珍国医国药,2012,23(2)：319-320.
［20］吴仪洛.本草从新［M］.北京：中国中医药出版社,2018：70.
［21］梁颖,李冀,郭盛磊,等.熟地黄多糖对荷瘤小鼠肿瘤组织Cyt-C及Caspase-3基因表达的影响［J］.中医药信息,2017,34(3)：24-27.
［22］朱庆均,郑广娟,张丹.白术水提物抑瘤作用及其机制研究［J］.山东中医药大学学报,2006，30(1)：69-71.
［23］王辉,孙桂芝.孙桂芝治疗骨肉瘤经验［J］.世界中医药,2012,7(1)：21-22.
［24］黄煜朗,唐毓金,王俊利,等.白花蛇舌草对人骨肉瘤MG-63细胞Bax基因表达的影响［J］.重庆医学,2014,43(35)：4708-4710.
［25］程海波,吴勉华.周仲瑛教授从癌毒辨治恶性肿瘤病机要素分析［J］.中华中医药学刊,2010,28(2)：313-316.
Memo
基金项目：国家中医药管理局建设项目(国中医药人教发〔2010〕59号)；江苏省六大人才高峰项目（RJFW-40）；江苏省“333高层次人才培养工程”（2018III-0121）；江苏省科技型企业技术创新资金（BC2015022）；南京中医药大学横向课题（2019035，2019010）南京健康广场健康产业开放课题（NJJKGC202204）；南京中医药大学中医学品牌专业建设2017年度教学改革研究课题（NZYZYXPPJH2017-04）